Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Table 7 Scenario analyses of PHiD-CV 2+1 versus no vaccination or PCV13 2+1 vaccination programs in Malaysia

Parameter	Base case	Scenario analysis	PHiD-CV versus no vaccination (ICER)	PHiD-CV versus PCV13 (cost saving [USD million]/QALYs gained)
Base case	–	–	28,497^a	5.2/116
Discount rate	3%	0%	23,792^a	5.7/125
Discount rate	3%	5%	31,793	4.9/110
AOM cases due to NTHi	32.3%	20.0%	30,843^a	3.1/60
Adjustment factor for total AOM cases	1.0	0.7	31,371	5.2/75
Adjustment factor for total AOM cases	1.0	1.3	26,105^a	5.2/157
Time horizon	10 years	100 years	10,317^b	5.2/50
Indirect effects	Excluded	Included	21,032^a	5.2/116

AOM acute otitis media, ICER incremental cost-effectiveness ratio, NTHi non-typeable H. influenzae, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine, QALY quality-adjusted life-year, USD United States dollars
^aCost-effective (<USD 30,999)
^bHighly cost-effective (<USD 10,333)

ISSN: 1478-7547